The post Ariana Grande’s Music Is Climbing Just Before Her Busy Era Begins Again appeared on BitcoinEthereumNews.com. Ariana Grande’s single “Yes, And?” and “Twilight Zone” both improve their standings, as does her most recent album Eternal Sunshine. HOLLYWOOD, CALIFORNIA – MARCH 10: Ariana Grande attends the 96th Annual Academy Awards on March 10, 2024 in Hollywood, California. (Photo by Sarah Morris/WireImage) WireImage Ariana Grande has a relatively quiet frame on the U.K.’s charts at the moment, with just a handful of entries – although in every instance, her music is climbing. The Grammy winner isn’t actively promoting anything at the moment, though that will change soon. She will once again team up with Cynthia Erivo for Wicked: For Good, the second installment of the Wicked franchise, which arrives this fall. A recently-announced concert tour, based around her latest chapter, is set to follow. Even as she remains mum for the moment, Grande’s music still manages to grow, and one tune returns as fans in the U.K. keep buying and streaming her latest wares. “Twilight Zone” Rises on Several Charts “Twilight Zone” improves on two sales-focused rankings this frame. The cut climbs from No. 31 to No. 23 on the Official Physical Singles chart, while on the Official Vinyl Singles roster, the track advances from No. 36 to No. 25. The single has now spent five weeks on each tally. It has previously peaked in the runner-up rung on the Official Physical Singles list and No. 3 on the Official Vinyl Singles roster. “Yes, And?” Returns Grande’s other win at the moment is a familiar one. “Yes, And?” reenters the Official Physical Singles chart at No. 87, extending its run as one of the top-selling tracks on any physical format to 58 weeks. The dance-pop smash has already reached No. 1, and it rejoins “Twilight Zone” this week to give the Grammy winner a pair of appearances on… The post Ariana Grande’s Music Is Climbing Just Before Her Busy Era Begins Again appeared on BitcoinEthereumNews.com. Ariana Grande’s single “Yes, And?” and “Twilight Zone” both improve their standings, as does her most recent album Eternal Sunshine. HOLLYWOOD, CALIFORNIA – MARCH 10: Ariana Grande attends the 96th Annual Academy Awards on March 10, 2024 in Hollywood, California. (Photo by Sarah Morris/WireImage) WireImage Ariana Grande has a relatively quiet frame on the U.K.’s charts at the moment, with just a handful of entries – although in every instance, her music is climbing. The Grammy winner isn’t actively promoting anything at the moment, though that will change soon. She will once again team up with Cynthia Erivo for Wicked: For Good, the second installment of the Wicked franchise, which arrives this fall. A recently-announced concert tour, based around her latest chapter, is set to follow. Even as she remains mum for the moment, Grande’s music still manages to grow, and one tune returns as fans in the U.K. keep buying and streaming her latest wares. “Twilight Zone” Rises on Several Charts “Twilight Zone” improves on two sales-focused rankings this frame. The cut climbs from No. 31 to No. 23 on the Official Physical Singles chart, while on the Official Vinyl Singles roster, the track advances from No. 36 to No. 25. The single has now spent five weeks on each tally. It has previously peaked in the runner-up rung on the Official Physical Singles list and No. 3 on the Official Vinyl Singles roster. “Yes, And?” Returns Grande’s other win at the moment is a familiar one. “Yes, And?” reenters the Official Physical Singles chart at No. 87, extending its run as one of the top-selling tracks on any physical format to 58 weeks. The dance-pop smash has already reached No. 1, and it rejoins “Twilight Zone” this week to give the Grammy winner a pair of appearances on…

Ariana Grande’s Music Is Climbing Just Before Her Busy Era Begins Again

Ariana Grande’s single “Yes, And?” and “Twilight Zone” both improve their standings, as does her most recent album Eternal Sunshine. HOLLYWOOD, CALIFORNIA – MARCH 10: Ariana Grande attends the 96th Annual Academy Awards on March 10, 2024 in Hollywood, California. (Photo by Sarah Morris/WireImage)

WireImage

Ariana Grande has a relatively quiet frame on the U.K.’s charts at the moment, with just a handful of entries – although in every instance, her music is climbing. The Grammy winner isn’t actively promoting anything at the moment, though that will change soon. She will once again team up with Cynthia Erivo for Wicked: For Good, the second installment of the Wicked franchise, which arrives this fall. A recently-announced concert tour, based around her latest chapter, is set to follow.

Even as she remains mum for the moment, Grande’s music still manages to grow, and one tune returns as fans in the U.K. keep buying and streaming her latest wares.

“Twilight Zone” Rises on Several Charts

“Twilight Zone” improves on two sales-focused rankings this frame. The cut climbs from No. 31 to No. 23 on the Official Physical Singles chart, while on the Official Vinyl Singles roster, the track advances from No. 36 to No. 25.

The single has now spent five weeks on each tally. It has previously peaked in the runner-up rung on the Official Physical Singles list and No. 3 on the Official Vinyl Singles roster.

“Yes, And?” Returns

Grande’s other win at the moment is a familiar one. “Yes, And?” reenters the Official Physical Singles chart at No. 87, extending its run as one of the top-selling tracks on any physical format to 58 weeks. The dance-pop smash has already reached No. 1, and it rejoins “Twilight Zone” this week to give the Grammy winner a pair of appearances on the tally.

Eternal Sunshine Inches North

Eternal Sunshine also manages some small progress. The set ticks up two spaces on both tallies where it appears, lifting to No. 81 on the Official Albums chart and to No. 73 on the Official Albums Streaming tally. Grande’s most recent full-length has now spent 72 and 73 weeks on those lists, respectively, and it became another champion for the superstar when it was new.

Source: https://www.forbes.com/sites/hughmcintyre/2025/09/03/ariana-grandes-music-is-climbing-just-before-her-busy-era-begins-again/

Market Opportunity
Sidekick Logo
Sidekick Price(K)
$0.005601
$0.005601$0.005601
+34.28%
USD
Sidekick (K) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23